Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Skin Cancers Caused by UV Acting on the Rb Pathway

By Biotechdaily staff writers
Posted on 12 Feb 2003
A recent study has revealed that the mechanism by which the sun's ultraviolet light stimulates the formation of skin cancer requires an intact Rb pathway. More...
The results were reported in the February 4, 2003, issue of the Proceedings of the National Academy of Sciences.

The term "Rb pathway” refers to the gene (RB1) for the retinoblastoma protein, pRb, which was the first mammalian tumor suppressor gene to be isolated. Data generated in the last decade have pointed to a crucial role for pRb in the regulation of fundamental cellular processes such as differentiation, proliferation and apoptosis. Genetic and biochemical data have placed pRb in a linear pathway. This pathway involves cyclin- dependent kinase (CDK) inhibitors of the INK4 family, which act as negative regulators of cell proliferation, and the positively acting D-type cyclins that in association with CDK4 or CDK6 form active kinase complexes. The downstream targets in the pathway are the E2F transcription factors.


The majority of human cancers harbor alterations in one of the genes in the pRb pathway as a result of an inactivating germline or somatic mutations in RB1 or p16INK4A, activating mutations in CDK4, and amplification or overexpression of the D-type cyclins and CDK4 or CDK6.

Investigators from the Dana-Farber Cancer Institute (Boston, MA, USA) exposed newborns of two strains of genetically engineered mice--one lacking a critical component of the p53 pathway, p19, and one lacking the Rb pathway protein p16--to UV radiation. (Both strains carried the Ras mutation, making them especially cancer-prone.) The p19 mutants, whose Rb pathway was intact, had a much higher chance of developing melanomas when exposed to UV radiation—85% compared to 50% in nonexposed litters. They also developed more tumors, two to three compared to one in the non-exposed group, and the lesions appeared, on average, six weeks sooner.

"It looks like the Rb pathway is specifically targeted by ultraviolet radiation,” explained senior author Dr. Lynda Chin, assistant professor of dermatology at Harvard Medical School. "If you see in a sun-induced lesion that its Rb pathway has been inactivated, then the risk of it becoming a melanoma is much greater than one without such a lesion. You could then use that as a prognostic factor to determine which of these funny-looking moles needs to be cut out with a wide margin around it.”



Related Links:
Dana-Farber Cancer Institute

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.